Track topics on Twitter Track topics that are important to you
Terence R. Flotte, MD, executive deputy chancellor, provost, and dean of the University of Massachusetts School of Medicine, presented the first signs of clinical benefit in an early-stage gene therapy trial for Tay-Sachs disease on two infants. Flotte said there are early signs that the therapy, which in 2018 was licensed to Axovant Gene Therapies, has the potential to modify the rate of disease progression.
The post Promising Results Reported in Tay-Sachs Gene Therapy Trial appeared first on GEN - Genetic Engineering and Biotechnology News.
Original Article: Promising Results Reported in Tay-Sachs Gene Therapy TrialNEXT ARTICLE
Biological therapy involves the use of living organisms, substances derived from living organisms, or laboratory-produced versions of such substances to treat disease. Some biological therapies for cancer use vaccines or bacteria to stimulate the body&rs...
Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...